**Table 3.** Multivariate analysis for locoregional control (LR), overall survival (OS) and disease-free survival (DFS) for entire cohort.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **LR** | | **OS** | | **DFS** | |
| **Covariate** | **Risk factor** | **HR (95%CI)** | ***p*** | **HR (95%CI)** | ***p*** | **HR (95%CI)** | ***p*** |
| **Age (years)** |  | 1.03 (1.00–1.07) | 0.05 | 1.05 (1.03–1.07) | <0.001 | 1.04 (1.02–1.06) | <0.001 |
| **Histology** | **non-endometrioid vs. endometrioid** | 1.65 (0.85–3.19) | 0.14 | 2.01 (1.36–2.96) | <0.001 | 1.90 (1.35–2.67) | <0.001 |
| **Grade** | **II–III vs. I** | 1.80 (0.88–3.65) | 0.11 | 1.44 (0.96–2.16) | 0.08 | 1.16 (0.81–1.67) | 0.42 |
| **LVSI** | **yes vs. no** | 1.17 (0.57–2.41) | 0.67 | 1.34 (0.87–2.06) | 0.18 | 1.13 (0.79–1.62) | 0.50 |
| **Myometrial invasion** | **≥1/2 vs. <1/2** | 1.59 (0.69–3.67) | 0.28 | 1.66 (1.03–2.67) | 0.04 | 1.61 (1.06–2.42) | 0.02 |
| **Stromal invasion** | **yes vs. no** |  |  | 1.81 (1.23–2.65) | 0.002 | 1.79 (1.29–2.50) | 0.001 |
| **Stage** | **III vs. I–II** |  |  | 1.00 (0.51–1.96) | 0.96 | 1.01 (0.58–1.76) | 0.97 |
| **Ln metastasis** | **yes vs. no** | 1.70 (0.91–3.18) | 0.10 | 1.87 (1.07–3.61) | 0.03 | 1.76 (1.03–3.01) | 0.04 |
| **Vaginal BRT** | **no vs. yes** | 1.85 (0.88–3.89) | 0.11 | 1.44 (0.93–2.22) | 0.10 | 1.26 (0.87–1.82) | 0.22 |
| **Chemotherapy** | **no vs. yes** |  |  | 1.03 (0.70–1.50) | 0.90 | 1.26 (0.90–1.77) | 0.18 |